WO2009034541A3 - Controlled release pharmaceutical dosage forms of trimetazidine - Google Patents

Controlled release pharmaceutical dosage forms of trimetazidine Download PDF

Info

Publication number
WO2009034541A3
WO2009034541A3 PCT/IB2008/053679 IB2008053679W WO2009034541A3 WO 2009034541 A3 WO2009034541 A3 WO 2009034541A3 IB 2008053679 W IB2008053679 W IB 2008053679W WO 2009034541 A3 WO2009034541 A3 WO 2009034541A3
Authority
WO
WIPO (PCT)
Prior art keywords
trimetazidine
dosage forms
controlled release
pharmaceutical dosage
release pharmaceutical
Prior art date
Application number
PCT/IB2008/053679
Other languages
French (fr)
Other versions
WO2009034541A9 (en
WO2009034541A2 (en
Inventor
Sweta Varshney
Anant Ramesh Katkar
Kalaiselvan Ramaraju
Rajan Kumar Verma
Rajeev Singh Raghuvanshi
Original Assignee
Ranbaxy Lab Ltd
Sweta Varshney
Anant Ramesh Katkar
Kalaiselvan Ramaraju
Rajan Kumar Verma
Rajeev Singh Raghuvanshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Sweta Varshney, Anant Ramesh Katkar, Kalaiselvan Ramaraju, Rajan Kumar Verma, Rajeev Singh Raghuvanshi filed Critical Ranbaxy Lab Ltd
Priority to EP08807614A priority Critical patent/EP2200591A2/en
Publication of WO2009034541A2 publication Critical patent/WO2009034541A2/en
Publication of WO2009034541A3 publication Critical patent/WO2009034541A3/en
Publication of WO2009034541A9 publication Critical patent/WO2009034541A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to new solid dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping.
PCT/IB2008/053679 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine WO2009034541A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08807614A EP2200591A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1925/DEL/2007 2007-09-11
IN1925DE2007 2007-09-11
IN1226DE2008 2008-05-16
IN1226/DEL/2008 2008-05-16

Publications (3)

Publication Number Publication Date
WO2009034541A2 WO2009034541A2 (en) 2009-03-19
WO2009034541A3 true WO2009034541A3 (en) 2009-07-30
WO2009034541A9 WO2009034541A9 (en) 2009-12-30

Family

ID=40120263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/053679 WO2009034541A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Country Status (2)

Country Link
EP (1) EP2200591A2 (en)
WO (1) WO2009034541A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
TR201001902A2 (en) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Trimetazidine tablets with extended release
EP2394644B1 (en) * 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
PL2611426T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (en) 2012-04-18 2019-01-14 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102824644B (en) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 High-stability sustained-release tablet prepared by using hydroxy propyl cellulose
AR096439A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
WO2015181059A1 (en) * 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2018094387A1 (en) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
US20180190374A1 (en) * 2017-01-03 2018-07-05 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury
CN109908096A (en) * 2017-12-12 2019-06-21 武汉武药科技有限公司 A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof
CN110623934B (en) * 2019-09-26 2022-05-13 杭州百诚医药科技股份有限公司 Trimetazidine hydrochloride sustained release tablet and preparation method thereof
CN111888476A (en) * 2020-08-17 2020-11-06 深圳市道科思医药有限公司 Modified release pharmaceutical composition of trimetazidine dihydrochloride

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistent tablets
AU684893B2 (en) * 1994-03-24 1998-01-08 Les Laboratoires Servier Pharmaceutical compositions permitting the prolonged release of trimetazidine after oral administraiton
EP1195160A1 (en) * 2000-10-05 2002-04-10 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
WO2002051417A1 (en) * 2000-12-26 2002-07-04 Les Laboratoires Servier Thermofomable solid pharmaceutical composition for controlled release of trimetazidine
AU780011B2 (en) * 1999-12-17 2005-02-24 Les Laboratoires Servier Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
WO2006123073A1 (en) * 2005-05-18 2006-11-23 Les Laboratoires Servier Sustained release solid pharmaceutical composition of 1-(2,3,4-trimethoxybenzyl)piperazine and a method for the preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043610A2 (en) 2001-11-21 2003-05-30 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistent tablets
AU684893B2 (en) * 1994-03-24 1998-01-08 Les Laboratoires Servier Pharmaceutical compositions permitting the prolonged release of trimetazidine after oral administraiton
AU780011B2 (en) * 1999-12-17 2005-02-24 Les Laboratoires Servier Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
EP1195160A1 (en) * 2000-10-05 2002-04-10 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
WO2002051417A1 (en) * 2000-12-26 2002-07-04 Les Laboratoires Servier Thermofomable solid pharmaceutical composition for controlled release of trimetazidine
WO2006123073A1 (en) * 2005-05-18 2006-11-23 Les Laboratoires Servier Sustained release solid pharmaceutical composition of 1-(2,3,4-trimethoxybenzyl)piperazine and a method for the preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198644, Derwent World Patents Index; AN 1986-289031, XP002529250 *
KRISHNAIAH Y S R ET AL: "Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 81, no. 1-2, 17 May 2002 (2002-05-17), pages 45 - 56, XP004351102, ISSN: 0168-3659 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol

Also Published As

Publication number Publication date
EP2200591A2 (en) 2010-06-30
WO2009034541A9 (en) 2009-12-30
WO2009034541A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
WO2011084593A3 (en) Abuse-resistant formulations
SI1695710T1 (en) Crystalline form beta-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
PL1695709T3 (en) Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
EP1974722A3 (en) Modified dosage forms of tacrolimus
WO2011106416A3 (en) Abuse-resistant formulations
WO2008049657A3 (en) Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
PT2205279E (en) Pharmaceutical combination of aliskiren and valsartan
WO2010066749A3 (en) Ulipristal acetate tablets
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
WO2010049449A3 (en) Novel salts of sunitinib
JP2010540547A5 (en)
SI2646011T1 (en) Methods for reducing binge or compulsive eating
WO2012052169A3 (en) Particulate pharmaceutical composition containing an opioid and an opioid antagonist
WO2019194773A3 (en) The combination comprising linagliptin and metformin
PT2231598E (en) Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same
WO2007070466A3 (en) In situ hyperpolarization of imaging agents
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
EP2212325A4 (en) 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same
WO2006127321A3 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807614

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008807614

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE